ClinicalTrials.gg
CompletedNCT01569841Updated Feb 18, 2016Results posted

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-18.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.

Enrollment
35th of 39
24 · median 38
Started
2012
with 3 others
Phase 3
7 of 39
none open now
Registered
19th of 39
by date
Lead sponsor
30 of 39
Novo Nordisk A/S

Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 35th largest by enrollment, is one of 4 that started in 2012, is one of 7 in phase 3, and was the 19th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy of insulin decludec with insulin glargine on glycaemic control using continuous glucose monitoring in patients with type 1 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 24 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes
  • (glycosylated ) below or equal to 8.5%
  • Current treatment with IGlar (insulin glargine) in a basal-bolus regimen with a total daily dose below 120 U
  • (body mass index) below 35 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Use within the last 3 months prior to visit 1 (screening) of any antidiabetic glucose lowering drug other than insulin/insulin analogues
  • Subjects with regular use of acetaminophen who are not willing to use another analgetic during CGM (Continuous Glucose Monitoring) periods
  • Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary arterial bypass graft or angioplasty within 24 weeks prior to visit 1
  • Recurrent severe hypoglycemia (more than one severe hypoglycemic event during the last 12 months) or hypoglycemia unawareness or hospitalization for diabetic ketoacidosis during the previous 6 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    IDeg

    Drug: insulin degludec

  • Active comparator
    IGlar

    Drug: insulin glargine

Interventions

  • Administered subcutaneously (s.c., under the skin) once daily.

  • Administered subcutaneously (s.c., under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)

    Time within the glycaemic target range \[\> 70 mg/dL (3.9 mmol/L) and \< 130 mg/dL (7.2 mmol/L)\] measured by Continuous Glucose Monitoring (CGM) in the last four hours of each dosing interval during the last 2 weeks of the 6-week treatment period.

    Time frame: CGM occured during the last 2 weeks of the 6 weeks treatment period.

Secondary outcomes

  1. Mean Interstitial Glucose (IG) Based on 14 Days of CGM

    The observed mean of IG profile was obtained as the average value of area under the IG profile divided by the actual assessment time interval during the last 2 weeks of the 6-week treatment period.

    Time frame: CGM monitoring occurred during the last 2 weeks of the 6-week treatment period.

  2. Fasting Plasma Glucose (FPG)

    FPG after 6 weeks of treatment in each treatment period.

    Time frame: At the end of each 6 week treatment period.

  3. Glycosylated Haemoglobin (HbA1c)

    HbA1c after 6 weeks of treatment in each treatment period.

    Time frame: At the end of each 6 week treatment period.

  4. Number of Treatment Emergent Adverse Events (AEs)

    Number of treatment emergent adverse events (TEAEs). An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.

    Time frame: Within each week 6 treatment period

  5. Number of Treatment Emergent Confirmed Hypoglycaemic Episodes

    A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product (IMP), and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Hypoglycemic episodes reported within each 6 week treatment period.

08

Results

Posted Nov 17, 2015

Participant flow

The trial was conducted at one site in the United States of America (USA).

Period A (6 Weeks)
Participant flow — Period A (6 Weeks)
MilestoneIDeg/IGlarIGlar/IDeg
Started1212
Exposed1212
Completed1211
Not completed01
Withdrew: Withdrawal by subject01
Period B (6 Weeks)
Participant flow — Period B (6 Weeks)
MilestoneIDeg/IGlarIGlar/IDeg
Started1211
Exposed1211
Completed1211
Not completed00

Outcome measures

PrimaryAverage Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)

Time within the glycaemic target range \[\> 70 mg/dL (3.9 mmol/L) and \< 130 mg/dL (7.2 mmol/L)\] measured by Continuous Glucose Monitoring (CGM) in the last four hours of each dosing interval during the last 2 weeks of the 6-week treatment period.

Time frame:
CGM occured during the last 2 weeks of the 6 weeks treatment period.
Reported as:
Mean · hours
Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)
hoursIDegIGlar
Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)1.39 ± 0.711.09 ± 0.77
SecondaryMean Interstitial Glucose (IG) Based on 14 Days of CGM

The observed mean of IG profile was obtained as the average value of area under the IG profile divided by the actual assessment time interval during the last 2 weeks of the 6-week treatment period.

Time frame:
CGM monitoring occurred during the last 2 weeks of the 6-week treatment period.
Reported as:
Mean · mmol/L
Mean Interstitial Glucose (IG) Based on 14 Days of CGM
mmol/LIDegIGlar
Mean Interstitial Glucose (IG) Based on 14 Days of CGM9.6 ± 1.59.8 ± 1.7
SecondaryFasting Plasma Glucose (FPG)

FPG after 6 weeks of treatment in each treatment period.

Time frame:
At the end of each 6 week treatment period.
Reported as:
Mean · mmol/L
Fasting Plasma Glucose (FPG)
mmol/LIDeg/IGlarIGlar/IDeg
Treatment period A8.8 ± 4.610.9 ± 4.8
Treatment period B10.4 ± 3.410.9 ± 4.4
SecondaryGlycosylated Haemoglobin (HbA1c)

HbA1c after 6 weeks of treatment in each treatment period.

Time frame:
At the end of each 6 week treatment period.
Reported as:
Mean · percentage of glycosylated haemoglobin
Glycosylated Haemoglobin (HbA1c)
percentage of glycosylated haemoglobinIDeg/IGlarIGlar/IDeg
Treatment period A6.6 ± 0.57.1 ± 0.6
Treatment period B6.9 ± 0.77.3 ± 0.6
SecondaryNumber of Treatment Emergent Adverse Events (AEs)

Number of treatment emergent adverse events (TEAEs). An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.

Time frame:
Within each week 6 treatment period
Reported as:
Number · events
Number of Treatment Emergent Adverse Events (AEs)
eventsIDegIGlar
Adverse Events1816
Serious Adverse Events00
Severe Adverse Events30
Moderate Adverse Events50
Mild Adverse Events1016
Fatal Adverse Events00
SecondaryNumber of Treatment Emergent Confirmed Hypoglycaemic Episodes

A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product (IMP), and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Hypoglycemic episodes reported within each 6 week treatment period.
Reported as:
Number · events
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
eventsIDegIGlar
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes283239

Adverse events

Collected over Treatment emergent adverse events were collected during each 6 week treatment period + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg—0/23 (0%)0/23 (0%)
IGlar—0/24 (0%)8/24 (33.3%)
Most frequent other events
Most frequent other events
EventIDegIGlar
NasopharyngitisInfections and infestations0/238/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Full Analysis Set
Mean45.3 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)Full Analysis Set
Female9
Male15
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mmol/L)Full Analysis Set
Mean10.7 ± 3.4
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)Full Analysis Set
Mean7.1 ± 0.6
09

Study locations

1 site
  • Novo Nordisk Clinical Trial Call Center
    Minneapolis, Minnesota 55416-2699, United States
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 3 years after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2012
First posted
Apr 3, 2012
Start
Apr 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results delay requested
Dec 19, 2012
Results first posted
Nov 17, 2015
Last update
Feb 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01569841
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 3, 2012
Start date
Apr 2012
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Nov 17, 2015
Last update
Feb 18, 2016

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion